GILD240920P84000
- 0.40
- -0.33-45.21%
Gilead Sciences Newsroom
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies Remains a Buy on Gilead Sciences (GILD)
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
Hold Rating on Gilead Sciences Amid Lenacapavir's Promise and Market Uncertainties
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $90
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating
Buy Rating Affirmed for Gilead Sciences on Lenacapavir's Market-Changing Potential in PrEP
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Raymond James Raises Gilead Sciences' Price Target to $94 From $93, Outperform Rating Maintained
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Piper Sandler Maintains Overweight on Gilead Sciences, Maintains $95 Price Target
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Analyst Holds Gilead Sciences Rating Amidst PURPOSE-2 Trial Uncertainties
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Gilead Sciences Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $95